Press Releases Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
5.46 ^USD	+6.02%		+18.70%	+28.17%

Jul. 02	Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency	MT
Jul. 02	Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency	Jul. 02	AQ
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)	Jun. 21	AQ
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference	May. 30	AQ
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences	May. 23	AQ
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference	May. 08	AQ
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights	May. 07	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	May. 06	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency	Apr. 08	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	AQ
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	AQ
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024	Mar. 26	AQ
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights	Mar. 12	AQ
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 26	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 06	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 05	AQ
Inozyme Pharma to Participate in Upcoming Investor Conferences	Nov. 09	AQ
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights	Nov. 07	AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Nov. 03	AQ
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023	23-10-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Press Releases

Filters